Results 1 to 10 of about 2,393 (138)

Typhoid conjugate vaccine implementation in India: A review of supportive evidence [PDF]

Vaccine: X
Background: Typhoid conjugate vaccines are available in the private market in India and are also recommended by the National Technical Advisory Group on Immunisation (NTAGI) for inclusion in India’s Universal Immunisation Programme in 2022 to control and
Vijayalaxmi V. Mogasale, Anish Sinha, Jacob John, Habib Hasan Farooqui, Arindam Ray, Tracey Chantler, Vittal Mogasale, Bhim Gopal Dhoubhadel, W John Edmunds, Andrew Clark, Kaja Abbas   +10 more
doaj   +6 more sources

Impact of the COVID-19 pandemic and typhoid conjugate vaccine introduction on typhoid fever in Nepal. [PDF]

PLoS Neglected Tropical Diseases
BackgroundWhile typhoid conjugate vaccines (TCV) offer promise for reducing risk in endemic settings, their population-level impact remains unclear.
Dipesh Tamrakar, Shiva Ram Naga, Esther Jung, Basudha Shrestha, Pratibha Bista Roka, Rabin Pokharel, Sabin Bikram Shahi, Aarjya Tara Bajracharya, Surendra K Mahadup, Nishan Katuwal, Kate Doyle, Jessica C Seidman, Alice S Carter, Stephen P Luby, Isaac I Bogoch, Kristen Aiemjoy, Denise O Garrett, Rajeev Shrestha, Jason R Andrews   +18 more
doaj   +4 more sources

Gateway to Typhoid Conjugate Vaccine Introduction in India and Beyond—Programmatic Effectiveness of a Public Sector Typhoid Conjugate Vaccine Campaign in Navi Mumbai [PDF]

Clinical Infectious Diseases, 2023
Megan E Carey, Carey Megan E
exaly   +4 more sources

Cost analysis of a nationwide typhoid conjugate vaccine campaign in Burkina Faso. [PDF]

PLoS ONE
BackgroundIn Burkina Faso, typhoid fever remains a major public health concern, particularly among children under 15. In January 2025, a nationwide campaign introduced the typhoid conjugate vaccine targeting children aged 9 months to 14 years. This study
Jean-Louis Koulidiati, Robert L Zoma, Eric I Nebié, Soumaila Yameogo, Christelle Neya Ouedraogo, Joël Arthur Kiendrébéogo, Frédéric Debellut   +6 more
doaj   +2 more sources

Development and validation of immunological assays for preclinical evaluation of a novel bivalent typhoid conjugate vaccine [PDF]

Human Vaccines & Immunotherapeutics
Currently there is no licensed bivalent typhoid conjugate vaccine against Salmonella Typhi (ST) and Salmonella Paratyphi A (SPT), which is a major public health concern causing enteric fever. Serum Institute of India Pvt. Ltd.
Vinay Gavade, Chandrashekhar Kamat, Nikhil Avalaskar, Vinod Haridasyam, Somnath Sargar, Avinash Chavan, Vaibhav Jadhav, Saurabh Kadam, Balu Borude, Annamraju D. Sarma, Asha Mallya, Rajeev M. Dhere   +11 more
doaj   +2 more sources

Implementation of an outbreak response vaccination campaign with typhoid conjugate vaccine – Harare, Zimbabwe, 2019 [PDF]

Vaccine: X, 2022
Introduction: Typhoid fever is a public-health problem in Harare, the capital city of Zimbabwe, with seasonal outbreaks occurring annually since 2010.
M. Poncin, J. Marembo, P. Chitando, N. Sreenivasan, I. Makwara, Z. Machekanyanga, W. Nyabyenda, I. Mukeredzi, M. Munyanyi, A. Hidle, F. Chingwena, C. Chigwena, P. Atuhebwe, H. Matzger, R. Chigerwe, A. Shaum, K. Date, D. Garone, P. Chonzi, J. Barak, I. Phiri, M. Rupfutse, K. Masunda, A. Gasasira, P. Manangazira   +24 more
doaj   +2 more sources

Development of invasive non-typhoidal Salmonella conjugate vaccines and their evaluation in a trivalent formulation with typhoid conjugate vaccine. [PDF]

Vaccine
Invasive nontyphoidal Salmonella (iNTS) infections, primarily caused by Salmonella enterica serovars Typhimurium (S. Typhimurium) and Enteritidis (S. Enteritidis), represent a significant public health concern, particularly in sub-Saharan Africa, where multidrug-resistant (MDR) strains are increasingly prevalent. Despite the substantial disease burden,
An SJ, Yang JS, Chae MH, Woo JS, Kang YE, Ganapathy R, Pansuriya RK, Choi JA, Yoon YK, Lee E, Lee SB, Pandey G, Lee JW, Lee JS, Bae SH, Kweon SW, Kim SJ, Seon SH, Kim JH, Song M.   +19 more
europepmc   +3 more sources

Knowledge, attitudes, and practices of the general population of Pakistan regarding typhoid conjugate vaccine: findings of a cross-sectional study [PDF]

Frontiers in Public Health, 2023
Typhoid fever, a common enteric disease in Pakistan, caused by Salmonella typhi, is becoming an extended drug-resistant organism and is preventable through the typhoid conjugate vaccine (TCV).
Muhammad Junaid Tahir, Musharaf Zaman, Junaid Saffi, Muhammad Sohaib Asghar, Waleed Tariq, Faizan Ahmed, Rabia Islam, Usman Shakeel Farooqui, Irfan Ullah, Muhammad Saqlain, Kaleem Ullah, Ali Ahmed   +11 more
doaj   +2 more sources

Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. [PDF]

N Engl J Med, 2021
Typhoid fever caused by multidrug-resistant H58 Salmonella Typhi is an increasing public health threat in sub-Saharan Africa.We conducted a phase 3, double-blind trial in Blantyre, Malawi, to assess the efficacy of Vi polysaccharide typhoid conjugate vaccine (Vi-TCV). We randomly assigned children who were between 9 months and 12 years of age, in a 1:1
Patel PD, Patel P, Liang Y, Meiring JE, Misiri T, Mwakiseghile F, Tracy JK, Masesa C, Msuku H, Banda D, Mbewe M, Henrion M, Adetunji F, Simiyu K, Rotrosen E, Birkhold M, Nampota N, Nyirenda OM, Kotloff K, Gmeiner M, Dube Q, Kawalazira G, Laurens MB, Heyderman RS, Gordon MA, Neuzil KM, TyVAC Malawi Team.   +26 more
europepmc   +6 more sources

A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E’s Vi-capsular polysaccharide-CRM197 conjugate typhoid vaccine (TyphiBEVTM) in healthy infants, children, and adults in comparison with a licensed comparator

Human Vaccines & Immunotherapeutics, 2022
The current scenario of typhoid fever warrants early prevention with typhoid conjugate vaccines in susceptible populations to provide lifelong protection.
Subhash Thuluva, Vikram Paradkar, Ramesh Matur, Kishore Turaga, Subba Reddy GV   +4 more
doaj   +2 more sources